Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Other Working Capital Changes (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Other Working Capital Changes for 12 consecutive years, with $16.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Other Working Capital Changes fell 99.97% year-over-year to $16.0, compared with a TTM value of -$121791.0 through Feb 2025, down 285.41%, and an annual FY2024 reading of -$89644.0, down 747.72% over the prior year.
  • Other Working Capital Changes was $16.0 for Q1 2025 at CNBX Pharmaceuticals, up from -$1653.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $243558.0 in Q2 2023 and bottomed at -$210033.0 in Q3 2023.
  • Average Other Working Capital Changes over 5 years is -$12828.0, with a median of -$11091.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes crashed 1494.01% in 2022, then skyrocketed 908.01% in 2023.
  • Year by year, Other Working Capital Changes stood at -$26203.0 in 2021, then surged by 89.75% to -$2687.0 in 2022, then crashed by 842.43% to -$25323.0 in 2023, then surged by 93.47% to -$1653.0 in 2024, then soared by 100.97% to $16.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for CNBX at $16.0 in Q1 2025, -$1653.0 in Q3 2024, and -$120154.0 in Q2 2024.